TOCILIZUMAB

tocilizumab 200 mg/10 mL injection, 10 mL vial

TOCILIZUMAB (1423X)

tocilizumab 200 mg/10 mL injection, 10 mL vial
1423X
Body System:
Manner of administration:Injection
Private
S100 HSD Private
Authority Required

Restriction

Indication: Systemic juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 1 (new patient)

Restriction

Indication: Systemic juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 2 (retrial or recommencement of treatment after a break of less than 12 months)

Restriction

Indication: Systemic juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 3 (recommencement of treatment after a break of more than 12 months)

Restriction

Indication: Systemic juvenile idiopathic arthritis
Treatment phase: Balance of supply for Initial treatment - Initial 1 (new patient) or Initial 2 (retrial or recommencement of treatment after a break of less than 12 months) or Initial 3 (recommencement of treatment after a break of more than 12 months)
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 0 DPMQ: $217.98 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Actemra
Avtozma